Neurological complications in Fabry disease

Revue de Medecine Interne

Volumn 31, Issue SUPPL. 2, 2010, Pages

  Dutsch M ^a   Hilz, M J ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autonomic dysfunction; Enzyme replacement therapy; Painful neuropathy; Quantitative sensory testing

Indexed keywords

AGALSIDASE BETA; ALPHA GALACTOSIDASE; AMITRIPTYLINE; CALCIUM CHANNEL; CARBAMAZEPINE; GABAPENTIN; GLYCOSPHINGOLIPID; LAMOTRIGINE; NARCOTIC ANALGESIC AGENT; PHENYTOIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ANHIDROSIS; ARTICLE; AUTONOMIC DYSFUNCTION; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; BURNING SENSATION; CEREBROVASCULAR DISEASE; COLD SENSATION; DISEASE SEVERITY; DISTAL PARESTHESIA; ENVIRONMENTAL TEMPERATURE; ENZYME REPLACEMENT; EXERCISE; FABRY DISEASE; GABAERGIC SYSTEM; HEAT SENSATION; HEAT TOLERANCE; HUMAN; MORTALITY; NERVE CONDUCTION; NEUROLOGIC DISEASE; NEUROMODULATION; NEUROPATHIC PAIN; NOCICEPTION; ORGAN PERFUSION; PAIN THRESHOLD; PATHOPHYSIOLOGY; PERCEPTIVE THRESHOLD; PREVALENCE; SKIN BLOOD FLOW; SODIUM CHANNELOPATHY; TRANSIENT ISCHEMIC ATTACK;

ALPHA-GALACTOSIDASE; COLD TEMPERATURE; ENZYME REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FABRY DISEASE; HOT TEMPERATURE; HUMANS; NEURALGIA; PAIN MEASUREMENT; PAIN THRESHOLD; PARESTHESIA; SEVERITY OF ILLNESS INDEX; STROKE; THERMOSENSING; TREATMENT OUTCOME;

EID: 78650728176     PISSN: 02488663     EISSN: 17683122     Source Type: Journal    
DOI: 10.1016/S0248-8663(10)70021-7     Document Type: Article

References (73)

1. Eng C., Desnick R. Molecular basis of Fabry disease: mutations and polymorphisms in the human alpha-galactosidase A gene. Hum Mut 1994, 3:103-111.
2. Morgan S.H., Rudge P., Smith S.J., Bronstein A.M., Kendall B.E., Holly E., et al. The neurological complications of Anderson-Fabry disease (alpha galactosidase A deficiency) - investigation of symptomatic and presymptomatic patients. Q J Med 1990, 75:491-507.
3. Lyon G., Adams R.D., Kolodny E.H. Neurology of hereditary metabolic diseases of children 1996, McGraw-Hill, New York, 224-6.
4. Brady R.O. Fabry Disease. Peripheral neuropathy 1993, 1169-1178. WB Saunders, Philadelphia. 3 ed. P.J. Dyck, P.K. Thomas, J.W. Griffin, P.A. Low, J.F. Poduslo (Eds.).
5. Brady R.O., Schiffmann R. Clinical Features and Recent Advances in Therapy for Fabry Disease. JAMA 2000, 284:2771-2775.
6. Grau A.J., Schwaninger M., Goebel H.H., Beck M. Morbus Fabry - Eine lysosomale Stoffwechselerkrankung mit neuen therapeutischen Möglichkeiten. Nervenarzt 2003, 489-496.
7. Mohanraj R., Leach J.P., Broome J.C., Smith D.F. Neurological presentation of Fabry's disease in a 52 year old man. J Neurol Neurosurg Psychiatry 2002, 73:340-342.
8. Mitsias P., Levine S.R. Cerebrovascular Complications of Fabry's Disease. Ann Neurol 1996, 40:8-17.
9. Grewal R. Stroke in Fabry's disease. J Neurol 1994, 241:153-156.
10. MacDermot J., MacDermot K.D. Neuropathic pain in Anderson- Fabry disease: pathology and therapeutic options. Eur J Pharmacol 2001, 429:121-125.
11. Dütsch M., Marthol H., Stemper B., Brys M., Haendl T., Hilz M.J. Small fiber neuropathy predominates in Fabry neuropathy. J Clin Neurophysiol 2002, 19:575-586.
12. sKaye E.M., Kolodny E.H., Logigian E.L., Ullman M.D. Nervous system involvement in Fabry's disease: clinicopathological and biochemical correlation. Ann Neurol 1988, 23:505-509.
13. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestation and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001, 38:750-760.
14. Crutchfield K.E., Patronas N.J., Dambrosia J.M., Frei K.P., Banerjee T.K., Barton N.W., et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998, 50:1746-1749.
15. Moore D.F., Ye F., Schiffmann R., Butman J.A. Increased signal intensity in the pulvinar on T1-weighted images: a pathognomonic sign of Fabry disease. Am J Neuroradiol 2003, 24:1096-1101.
16. Moore D.F., Scott L.T., Gladwin M.T., Altarescu G., Kaneski C., Suzuki K., et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy. Circulation 2001, 104:1506-1512.
17. Moore D.F., Altarescu G., Ling G.S., Jeffries N., Frei K.P., Weibel T., et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002, 33:525-531.
18. Moore D.F., Altarescu G., Herscovitch P., Schiffmann R. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BNC Neurology 2002, 2:4.
19. DeGraba T., Azhar S., Dignat-George F., Brown E., Boutiere B., Altarescu G., et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000, 47:229-233.
20. Perrot X., Nighoghossian N., Derex L., Hermier M., Guffon N., Boulliat J., et al. Vertebro-basilar ischemic strokes and aseptic meningitis, late complications of Fabry's disease. Rev Neurol (Paris) 2002, 158:596-598.
21. Cleeland C.S. Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 2002, 91:43-47.
22. Schiffmann R., Scott L.J. Pathophysiology and assessment of neuropathic pain in Fabry disease. Acta Paediatr Suppl 2002, 91:48-52.
23. Scott L.J., Griffin J.W., Luciano C., Barton N.W., Banerjee T., Crawford T., et al. Quantitative analysis of epidermal innervation in Fabry disease. Neurology 1999, 52:1249-1254.
24. MacDermot K.D., Holmes A., Miners A.H. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate female carriers. J Med Genet 2001, 38:769-807.
25. Beck M., Whybra C., Wendrich K., Gal A., Ries M. Anderson-Fabry disease in children and adolescents. Contrib Nephrol 2001, 136:251-255.
26. Hilz M.J., Stemper B., Kolodny E.H. Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients. Pain 2000, 84:361-365.
27. Dyck P.J., Karnes J., O'Brien P.C., Zimmerman I.R. Detection thresholds of cutaneous sensation in humans. Peripheral neuropathy 1993, 706-728. WB Saunders, Philadelphia. 3 ed. P.J. Dyck, P.K. Thomas, J.W. Griffin, P.A. Low, J.F. Poduslo (Eds.).
28. Dyck P.J., O'Brien P.C., Kosanke J.L., Gillen D.A., Karnes J.L. A 4, 2, and 1 stepping algorithm for quick and accurate estimation of cutaneous sensation thresholds. Neurology 1993, 43:1508-1512.
29. Dyck P.J., Zimmerman I., Gillen D.A., Johnson D., Karnes J.L., O'Brien P.C. Cool, warm, and heat-pain detection thresholds: Testing methods and inferences about anatomic distribution of receptors. Neurology 1993, 43:1500-1508.
30. Dyck P.J., Zimmerman I.R., Johnson D.M., Gillen D., Hokanson J.L., Karnes J.L., et al. A standard test of heat-pain responses using CASE IV. J Neurol Sci 1996, 136:54-63.
31. Hilz M.J., Claus D., Neundorfer B. Early diagnosis of diabetic small fiber neuropathy by disturbed cold perception. J Diabet Complications 1988, 2:38-43.
32. Hilz M.J. Assessment of peripheral and autonomic neuropathy in Fabry disease. Acta Paediatr Suppl 2002, 91:38-42.
33. Cable W.J., Kolodny E.H., Adams R.D. Fabry disease: impaired autonomic function. Neurology 1982, 32:498-502.
34. Cable W.J., Dvorak A.M., Osage J.E., Kolodny E.H. Fabry disease: significance of ultrastructural localization of lipid inclusions in dermal nerves. Neurology 1982, 32:347-353.
35. Lao L.M., Kumakiri M., Mima H., Kuwahara H., Ishida H., Ishiguro K., et al. The ultrasttructural characteristics of eccrine sweat glands in a Fabry disease patient with hypohydrosis. J Dermatol Sci 1998, 18:109-117.
36. Inagaki M., Ohno K., Hisatome I., Tanaka Y., Takeshita K. Relative hypoxia of the extremities in Fabry disease. Brain Dev 1992, 14:328-333.
37. Thomas P.K. The anatomical substratum of pain evidence derived from morphometric studies on peripheral nerve. Can J Neurol Sci 1974, 1:92-97.
38. Birklein F. Mechanisms of neuropathic pain and their importance in Fabry disese. Acta Paediatr Suppl 2002, 91:34-37.
39. Gemignani F., Pietrini V., Tagliavini F., Lechi A., Neri T.M., Asinari A., et al. Fabry's disease with familial lymphedema of the lower limb. Case report and family study. Eur Neurol 1979, 18:84-90.
40. Gadoth N., Sandbank U. Involvement of dorsal root ganglia in Fabry's disease. J Med Genet 1983, 20:309-312.
41. Sima A., Robertson D. Involvement of peripheral nerve and muscle in Fabry disease. Arch Neurol 1978, 35:291-301.
42. Bischoff A., Fierz U., Regli F., Ulrich J. [Peripheral neurological disorders in Fabry's disease (angiokeratoma corporis diffusum universale). Clinical and electron microscopic findings in a case]. Klin Wochenschr 1968, 46:666-671.
43. Kocen R.S., Thomas P.K. Peripheral nerve involvement in Fabry's disease. Arch Neurol 1970, 22:81-88.
44. Ohnishi A., Dyck P.J. Loss of small peripheral sensory neurons in Fabry disease. Arch Neurol 1974, 31:120-127.
45. Amir R., Michaelis M., Devor M. Membrane potential oscillations in dorsal root ganglion neurons: role in normal electrogenesis and neuropathic pain. J Neuro Sci 1999, 19:8589-8596.
46. Dib-Hajj S.D., Fjell J., Cummins T.R., Zheng Z., Fried K., LaMotte R., et al. Plasticity of sodium channel expression in DRG neurons in the chronic constriction injury model of neuropathic pain. Pain 1999, 83:591-600.
47. Tal M., Wall P.D., Devor M. Myelinated afferent fiber types that become spontaneously active and mechanosensitive following nerve transection in the rat. Brain Res 1999, 824:218-223.
48. Backonja M.M. Anticonvusants (antineuropathics) for neuropathic pain syndromes. Clin J Pain 2000, 16:S67-S72.
49. Brau M.E., Dreimann M., Olschewski A., Vogel W., Hempelmann G. Effect of drugs used for neuropathic pain management on tetrodotoxin-resistant Na+ currents in rat sensory neurons. Anesthesiology 2001, 94:137-144.
50. Le-Bars D., Dickenson A.H., Besson J.M. Diffuse noxious inhibitory controls (DNIC). I. Effects on dorsal horn convergent neurones in the rat. Pain 1979, 6:283-304.
51. Carriedo S.G., Yin H.Z., Sensi S.L., Weiss J.H. Rapid Ca2+ entry through Ca 2± permeable AMPA/Kainate channels triggers marked intracellular Ca2+ rises and consequent oxygen radical production. J Neurosci 1998, 18:7727-7738.
52. Xu X.J., Puke M.J., Verge V.M., Wiesenfeld-Hallin Z., Hughes J., Hokfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain in the rat. Neurosci Lett 1993, 152:129-132.
53. Dickenson A.H., Mathews E.A., Suzuki R. Central nervous system mechanisms of pain in peripheral neuropathy. Neuropathic pa pathophysiology treatment 2001, 85-106. IASP Press, Seattle. P.T. Hansson, H.L. Fields, R.G. Hill, P. Marchettini (Eds.).
54. Woolf C.J., Mannion R.J. Neuropathic pain: aetiology, symptoms, mechanisms, and management. Lancet 1999, 353:1959-1964.
55. Sato J., Perl E.R. Adrenergic excitation of cutaneous pain receptors induced by peripheral nerve injury. Science 1991, 251:1608-1610.
56. Birklein F., Weber M., Neundorfer B. Increased skin lactate in complex regional pain syndrome: evidence for tissue hypoxia?. Neurology 2000, 55:1213-1215.
57. Levine J.D., Taiwo Y.O., Collins S.D., Tam J.K. Noradrenaline hyperalgesia is mediated through interaction with sympathetic postganglionic neurone terminals rather than activation of primry afferent nociceptors. Nature 1986, 323:158-160.
58. Li Y., Dorsi M.J., Meyer R.A., Belzberg A.J. Mechanical hyperalgesia after an L5 spinal nerve lesion in the rat is not dependent on input from injured nerve fibers. Pain 2000, 85:493-502.
59. Schafers M., Brinkhoff J., Neukirchen S., Marziniak M., Sommer C. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor- alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001, 310:113-116.
60. Birklein F., Schmelz M., Schifter S., Weber M. The important role of neuropeptides in complex regional pain syndrome. Neurology 2001, 57:2179-2184.
61. Dyck P.J., Karnes J.L., Gillen D.A., O'Brien P.C., Zimmerman I.R., Johnson D.M. Comparison of algorithms of testing for use in automated evaluation of sensation. Neurology 1990, 40:1607-1613.
62. Dyck P.J., Dyck P.J.B., Velosa J.A., Larson T.S., O'Brien P.C. Patterns of quantitative sensation testing of hypoesthesia and hyperalgesia are predictive of diabetic polyneuropathy. Diabetes Care 2000, 23:510-517.
63. Baser S. Sudomotor function in autonomic failure. Neurology 1991, 41:1564-1566.
64. Schondorf R. Skin potentials: Normal and abnormal. Clinical Autonomic Disorders 1997, 221-232. Lippincott-Raven, Philadelphia. 2nd ed. P.A. Low (Ed.).
65. Shahani B.T., Halperin J.J., Boulu P., Cohen J. Sympathetic skin response - a method of assessing unmyelinated axon dysfunction in peripheral neuropathies. J Neurol Neurosurg Psychiatry 1984, 47:536-542.
66. Hilz M.J., Stemper B., Axelrod F.B. Sympathetic skin response differentiates hereditary sensory autonomic neuropathies III and IV. Neurology 1999, 52:1652-1657.
67. Hilz M.J. Quantitative autonomic functional testing in clinical trials. Clinical Neurophysiology and Neuromuscular Disease 2002, 1899-1929. WB Saunders, Philadelphia. W. Brown, C. Bolton, M. Aminoff (Eds.).
68. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., et al. Safety and efficacy of recombinant human alpha-galactosidase A - replacement therapy in Fabry's disease. N Engl J Med 2001, 345:9-16.
69. Hokanson D.E., Sumner D.S., Strandness D.E. An electrically calibrated plethysmograph for direct measurement of limb blood flow. IEEE Trans Biomed Eng 1975, 22:25-29.
70. Stemper B., Hilz M.J. Postischemic cutaneous hyperperfusion in the presence of forearm hypoperfusion suggest sympathetic vasomotor dysfunction in Fabry disease. J Neurol 2003, 250:970-976.
71. Watson C.P. The treatment of neuropathic pain: antidepressants and opioids. Clin J Pain 2000, 16:S49-55.
72. Schiffmann R., Kopp J.B., Austin HAr, Sabnis S., Moore D.F., Weibel T., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
73. Hilz M.J., Brys M., Marthol H., Stemper B., Dutsch M. Enzyme replacement therapy improves function of C - Adelta -, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004, 62:1066-1072.